• Facebook
  • Twitter
  • Instagram
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
MYELOMA360
  • Home
  • News
  • Education
    • Conference Coverage
      • ASCO & EHA 2019
      • EHA 2018
      • ASH 2017
    • CME & Webcasts
  • Events
  • Resources
    • Practice Resources
    • Patient Information
      • Product Education
      • Books
  • Videos
Select Page

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin

by | Dec 2, 2023 | Publications

Oncotarget. 2023 Dec 1;14:949-956. doi: 10.18632/oncotarget.28538. ABSTRACT In myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows good overall...

Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden – a feasibility study

by | Dec 1, 2023 | Publications

Radiol Oncol. 2023 Nov 30;57(4):455-464. doi: 10.2478/raon-2023-0048. eCollection 2023 Dec 1. ABSTRACT BACKGROUND: The purpose of our study was to explore and compare the tumor burden of different bone marrow infiltration patterns and evaluate the feasibility of...

An Incidental Finding of Pulmonary Cement Embolism Four Weeks After Vertebroplasty in a 50-Year-Old Man with Multiple Myeloma

by | Dec 1, 2023 | Publications

Am J Case Rep. 2023 Dec 1;24:e941716. doi: 10.12659/AJCR.941716. ABSTRACT BACKGROUND Vertebroplasty is a minimally invasive radiological procedure that involves injection of cement to stabilize the fractured vertebra. It has also been increasingly used to relieve pain...

Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)

by | Dec 1, 2023 | Publications

Curr Res Transl Med. 2023 Oct 24;71(4):103427. doi: 10.1016/j.retram.2023.103427. Online ahead of print. ABSTRACT Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells (PCs) in the bone marrow. Despite considerable advances in the...

The Role of Autologous Stem Cell Transplant in Ultra-High-Risk Myeloma: Do the Ends Still Justify the Means?

by | Dec 1, 2023 | Publications

Transplant Cell Ther. 2023 Dec;29(12):727-729. doi: 10.1016/j.jtct.2023.11.004. NO ABSTRACT PMID:38035888 | DOI:10.1016/j.jtct.2023.11.004

Total Gastrectomy for Gastric Invasion of Multiple Myeloma-A Case Report

by | Dec 1, 2023 | Publications

Gan To Kagaku Ryoho. 2023 Oct;50(10):1120-1122. ABSTRACT A 65-year-old woman was referred to our hospital for lumbago. The patient was diagnosed with multiple myeloma in 2020. She underwent chemotherapy and radiation therapy, and the disease progression stabilized. In...
« Older Entries
Next Entries »

Recent Content

  • Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
  • Advances in the pathogenesis of multiple myeloma bone disease
  • Association Between Circulating 25-Hydroxy Vitamin D Receptor and Molecular Response in Multiple Myeloma
  • Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
  • Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib, cyclophosphamide, and dexamethasone
  • Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities
  • Side Effects of Bone Strengtheners: Multiple Myeloma
  • Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression
  • Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
  • Apparent diffusion coefficient measurements of bone marrow infiltration patterns in multiple myeloma for the assessment of tumor burden – a feasibility study
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
  • Facebook
  • Twitter
  • Instagram
©2016-2023 MYELOMA360 & MindWrap Medical, LLC
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT